TRAIL Receptor-Induced Cell Death Regulation: An Update to Our Deadly Discussion
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | TRAIL Receptor-Induced Cell Death Regulation: An Update to Our Deadly Discussion |
| Type de publication | Book Chapter |
| Year of Publication | 2014 |
| Auteurs | Micheau O, Shirley S, Morizot A |
| Editor | AttaUrRahman, Zaman K |
| Book Title | TOPICS IN ANTI-CANCER RESEARCH, VOL 3 |
| Series Title | Topics in Anti-Cancer Research |
| Volume | 3 |
| Pagination | 3-36 |
| Publisher | BENTHAM SCIENCE PUBL |
| City | EXECUTIVE STE Y-2, P.O. BOX 7917, SAIF ZONE, SHARJAH, 1400 AG, U ARAB EMIRATES |
| ISBN Number | 978-1-60805-908-9; 978-1-60805-909-6 |
| ISBN | 2468-5860 |
| Mots-clés | APO2L, C-FLIP, Cancer, caspase, Chemotherapy, death domain, death effector domain, DISC, DR4, DR5, FADD, Glycosylation, Lexatumumab, Mapatumumab, scaffold, therapy, TRAIL, TRAIL-R1, TRAIL-R2, TRAIL-R4 |
| Résumé | The use of TRAIL/APO2L, monoclonal antibodies or peptidomimetics targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs, in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature chapter is an update to our article ``Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion'', published in the journal `Recent Patents on Anti-Cancer Drug Discovery', Volume 6, Number 3, September, 2011, Page 311 to 323, reviewing TRAIL DISC components that have been shown to regulate tumor cell fate upon TRAIL engagement. |